Market Report Source

Overview

In recent years, the biopharmaceutical industry has emerged as one of the most important sectors in the Healthcare field. Advances in life sciences have resulted in the drug discovery process becoming more science-intensive, with an increasing emphasis on cross-company collaborations and the exchange of information. However, growing commercial pressures and rising R&D costs have prompted many biotech companies to seek financial support from global Big Pharma corporations through licensing and collaborative R&D deals. Progressive enhancements in integration have subsequently led to traditional pharma companies becoming increasingly dependant upon the technology platforms and approaches adopted by biotech companies.

The Fastest Growing Biotechnology Companies: Growth Strategies, Comparative Analyses and Company Profiles is a new report published by Business Insights that examines the structure and organization of the biopharmaceutical industry with a detailed analysis of the fastest growing biotechnology companies. This report provides a comparative analysis of growth strategies and reviews the methods used to improve operational efficiency in light of cost pressures, generic competition, complex pricing, regulations, and globalization. This report also explores the levels of interaction and integration between biopharma companies and the wider pharma industry. Use key indicators to assess the performances of the fastest growing biotech companies, benchmark their most successful strategies and understand major industrial issues with this new report.

Top five reasons to order your copy today

• Identify the fastest growing biotech companies over the 2002-06 period, and use detailed company analysis to measure the performances and outlooks of major players including Theravance, ISTA, Palatin, Pharmion, Amylin, Trimeris, ViroPharma, NPS, SIGA and Idenix.
• Discover which therapeutic areas have been targeted by the fastest growing biotech companies and determine which strategies they have used to exploit proprietary technologies and intellectual property.
• Review the progress of biotech development programs and understand the regulatory status of new products in development, patents held and the current status of marketed products.
• Benchmark the strategies of the fastest growing biotech companies with this report’s assessment of the effectiveness and wider implications of a host of leading strategic implementations.
• Understand how biopharma drug discovery programs are being improved to develop more efficient methods in the screening of new chemical entities (NCEs).

Key issues examined in this report

• Biotech losses. Only eleven of the world’s top twenty biotechnology companies currently attain a positive net income. This trend is a key industry-wide issue, with companies now attempting to stabilize financial performance.
• Developmental uncertainty. Biotherapeutic developments continue to face a high level of uncertainty. A wide array of factors can contribute to the delay or late-stage failure of promising products.
• External investment. Time-consuming, risky and expensive biopharma product developments require high levels of investment and investor patience, as market-generated revenues are often late in materializing. Investors often pursue milestone payments, joint ventures, out-licensing deals, or M&A as alternative exit strategies.
• Partnership trends. The majority of dedicated biotech companies have attempted to establish strategic alliances, joint ventures and even mergers between themselves and major pharma companies.

Some key findings from this report

• Theravance, Inc. is the fastest growing biotechnology company in the world, with a growth rate of 12,456% over the 2002-06 period. However, Theravance also has one of the highest levels of net losses within the industry, highlighting the need to sustain more stable, predictable and stronger financial performance.
• ISTA Pharmaceuticals, Inc is the world’s second fastest growing biotechnology company, with a growth rate of 11,773% between 2002-06. Palatin Technologies, Inc. is in third position with a growth rate of 6,928% during the same period.
• Amylin Pharmaceuticals, Inc. recorded the greatest sales gains over 2002-2006, with an increase of $497.4mn during this period.
• The top 10 fastest growing biotechnology companies had a combined R&D expenditure of $734mn in 2006. This constitutes an increase of $324.7mn since 2002, and a five year growth rate of 179%.
• Flexible or adaptive clinical trial designs and proprietary Internet applications are helping to bring products to market faster by improving the efficiency of clincial trials. A prominent example of this is MetaTrial’s Electronic Data Capture (EDC) software.

Your questions answered

• Who are the fastest growing biotechnology companies in the world?
• What is their level of R&D expenditure and how does this compare to their revenues?
• What proportion of biotech company revenues are accounted for by marketed products?
• What license agreements, joint ventures and partnerships have been established by the fastest growing biotech companies?
• How profitable is the biopharmaceutical industry?
• What key strategic tactics are being adopted by the fastest growing biotech companies in R&D, product commercialization, cost containment, manufacturing and screening/development of NCEs?
• What are the strengths, weaknesses, opportunities and threats to each of the companies profiled within this report?
• What is the product pipeline status of major biotech companies?

Table of Contents

Executive Summary 16
Summary of key findings 16
Comparitive analyses of growth strategies 17
Theravance, Inc – company profile and analysis 18
ISTA Pharmaceuticals – company profile and analysis 19
Palatin Technologies – company profile and analysis 20
Pharmion Corporation – company profile and analysis 21
Amylin Pharmaceuticals – company profile and analysis 22
Trimeris, Inc – company profile and analysis 23
ViroPharma Inc – company profile and analysis 24
NPS Pharmaceuticals – company profile and analysis 25
SIGA Technologies, Inc – company profile and analysis 26
Idenix Pharmaceuticals – company profile and analysis 27

Chapter 1 Key findings and industry analysis 30
Summary 30
Overview of the biotechnology sector 31
Recent developments 32
Current applications 33
Structure of the biotechnology industry 35
The pharmaceutical-biopharmaceutical relationship 35
Emergence of the biopharmaceutical sector 36
Characteristics of the biopharmaceutical industry 40
Collaborative corporate environment 40
Highly technology and intellectual property 41
High venture capital investment 42
High risk and costs associated with drug development 42
Identifying fast growth companies- Methodology 44
Purpose and value of the analysis 45
Candidates identified as fast growth companies 46

Chapter 2 Comparitive analyses of growth strategies 48
Summary 48
The Fastest Growing Biopharmaceutical Companies 49
The evolving nature of the biopharmaceutical industry 56
Comparative analysis of R&D strategies 57
Revenue versus R&D expenditure 57
Early Phase R&D Strategies 60
Late Stage Clinical Development 61
Sponsored Research Payment Strategies 62
Analysis by Therapeutic Area 64
Comparative analysis of commercialization strategies 67
Platform positioning 67
The modern extended biopharmaceutical enterprise 71
Comparative analysis of manufacturing strategies 74
Comparion of restructuring and cost containment strategies 75
Case Study: Downsizing R&D at Trimeris, Inc. 76

Chapter 3 Theravance, Inc. 79
Summary 79
Company address and contact details 80
Company overview and history 80
Business profile 81
Discussion and analysis of financial data 81
Source and details of income 81
Review of proprietary technologies 83
Patents and proprietary rights 83
Strategic approach and positioning 83
Strategic approach 83
SWOT Analysis 84
Strengths 84
Weaknesses 85
Opportunities 85
Threats 86
Joint ventures, collaborations and M&A activity 87
Theravance’s collaboration with GlaxoSmithKline (GSK) 87
License, development and commercialization agreement with Astellas 88
License agreement with AstraZeneca AB 88
Product development programs 88
Bacterial infections 88
Telavancin 89
TD-1792 89
Respiratory 90
Horizon program (formerly Beyond Advair) 90
Inhaled bifunctional muscarinic anatgonist-beta2 agonist (MABA)
program 91
Inhaled long-acting muscarinic antagonist (LAMA) program 91
Gastrointestinal motility disorders 92
Research programs 92

Chapter 4 ISTA Pharmaceuticals, Inc. 96
Summary 96
Company Address and Contact Details 97
Company overview and history 97
Business profile 99
Discussion and analysis of financial data 99
Source and details of income 100
Review of proprietary technologies 100
Patents and proprietary rights 101
Strategic approach and positioning 104
Strategic approach 104
SWOT analysis 105
Strengths 105
Weaknesses 105
Opportunities 106
Threats 107
Joint ventures, collaborations and M&A activity 108
Xibrom, Istalol, Bepotastine, Ecabet Sodium, Latanoprost and Iganidipine
collaborations with Senju 108
Vitrase commercialization outside the US 108
Collaboration with Otsuka Pharmaceutical 109
Marketed products 109
Xibrom™ (bromfenac) 109
Istalol® 110
Vitrase® 111
Product development programs 111
T-Pred (tobramycin and prednisolone acetate combination product) 112
Bepotastine 112
Ecabet sodium 113
Strong steroid product 113

Chapter 5 Palatin Technologies Inc 118
Summary 118
Company address and contact details 119
Company overview and history 119
Business profile 120
Discussion and analysis of financial data 120
Source and details of income 121
Review of proprietary technologies 121
Patents and proprietary rights 122
Strategic approach and positioning 124
Strengths 124
Strength in MC expertise 124
Weaknesses 124
Termination of collaborative agreement with King Pharmaceuticals 124
Limited product pipeline portfolio 125
Opportunities 125
Threats 125
Joint ventures, collaborations and M&A activity 126
Strategic alliance with AstraZeneca AB 126
Collaborative development and marketing agreement with King
Pharmaceuticals 126
Strategic collaboration agreement with Mallinckrodt 127
Product development programs 128
Bremelanotide (formerly PT-141) 129
Male sexual dysfunction (MED) 129
Female sexual dysfunction (FSD) 129
Development of novel natriuretic receptor compounds 129

Chapter 6 Pharmion Corporation 134
Summary 134
Company address and contact details 135
Company overview and history 135
Business profile 138
Discussion and analysis of financial data 138
Source and details of income 138
Review of proprietary technologies 139
Patents and proprietary rights 140
Strategic approach and positioning 142
Strengths 142
Vidaza: potential future growth and revenue opportunities 142
Formation of strategic alliances 142
Weaknesses 143
Lack of manufacturing capabilities 143
Opportunities 144
Acquisition by Celgene 144
Inorganic growth 144
FDA approval of Vidaza NDA supplement for IV administration 144
Threats 145
Litigations 145
Intense competition 145
Cost containment pressures 146
Joint ventures, collaborations and M&A activity 147
M&A history 147
Acquisition of Cabrellis Pharmaceuticals 147
Joint ventures and collaborations 148
Marketed products 148
Vidaza (azacitidine for injection) 148
Thalidomide Pharmion 149
Innohep 149
Refludan 150
Product development programs 152
Amrubicin 152
Oral azacitidine 152
Satraplatin 152
MGCD0103 153

Chapter 7 Amylin Pharmaceuticals, Inc. 158
Summary 158
Company address and contact details 159
Company overview and history 159
Business profile 160
Discussion and analysis of financial data 160
Source and details of income 162
Review of proprietary technologies 162
Patents and proprietary rights 163
Strategic approach and positioning 164
Strengths 164
Strategic alliances 164
Byetta 164
New management team 165
Weaknesses 165
Reliance on third party manufacturers 165
Narrow customer concentration 166
Opportunities 167
Exenatide (long acting release) LAR 167
INTO obesity program 167
Threats 168
Competition 168
Joint ventures, collaborations and M&A activity 168
Joint ventures and collaborations 168
Marketed products 169
Byetta (exenatide) injection 169
Symlin 170
Product development programs 173
Diabetes product development 173
Exenatide LAR program 173
Obesity product development program 173
Pramlintide 173
Pramlintide and Leptin 174
Pramlintide PYY 3-36 174

Chapter 8 Trimeris, Inc. 178
Summary 178
Company address and contact details 179
Company overview and history 179
Business profile 181
Discussion, analysis of financial data 181
Details of income 181
Review of proprietary technologies 183
Patents and proprietary rights 183
Strategic approach and positioning 183
Strengths 184
Collaboration with Roche 184
Fuzeon 185
Weaknesses 185
T-1249 on hold 185
Opportunities 186
HIV drugs market 186
TRI-1144 186
Strategic shift in the company’s focus 187
Threats 188
Market acceptance of Fuzeon 188
Intense competition 188
Joint ventures, collaborations and M&A activity 189
Joint ventures and collaborations 189
Marketed products 190
Fuzeon 190
Product development programs 191
FUZEON 191
T-1249 191
Next generation fusion inhibitor peptide drug candidates 191

Chapter 9 ViroPharma Inc. 196
Summary 196
Company address and contact details 197
Company overview and history 197
Business profile 198
Discussion and analysis of financial data 198
Source and details of income 201
Review of proprietary technologies 201
Patents and proprietary rights 201
Strategic approach and positioning 202
Strengths 202
Strategic partnerships 202
Fast track status 203
Weaknesses 204
Lack of manufacturing capabilities 204
Customer concentration 204